Business Context and Reporting Period
Company: Gladstone Capital Corporation (GLAD)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009
Business Model: Closed-end, non-diversified management investment company operating as a Business Development Company (BDC) and Regulated Investment Company (RIC). The Company invests primarily in debt securities of established private businesses.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2009 | Six Months Ended Mar 31, 2009 | Net Assets (Mar 31, 2009) |
|---|---|---|---|
| Total Investment Income | $10.93 million | $22.74 million | $255.21 million |
| Net Investment Income | $5.56 million | $11.44 million | |
| Net Increase in Net Assets from Operations | $10.28 million | $1.18 million | |
| Net Assets Per Share | $12.10 | $12.10 | |
| Portfolio Investments (Fair Value) | $385.10 million | ||
| Portfolio Investments (Cost) | $444.56 million | ||
| Debt (Line of Credit) | $153.37 million | ||
| Asset Coverage Ratio | 266% | ||
| Cash and Equivalents | $10.53 million |
Material Changes vs. Prior Period
- Operating Results: The Company reported a net increase in net assets of $10.28 million for the quarter ended March 31, 2009, a significant improvement from a net decrease of $11.90 million in the same period of 2008. This turnaround was driven by net unrealized appreciation of $6.73 million on investments, compared to unrealized depreciation of $18.35 million in the prior year.
- Investment Income: Total investment income decreased slightly to $10.93 million from $11.35 million year-over-year, primarily due to a reduction in the weighted average yield (9.7% vs. 10.1%) and a decrease in the cost basis of the portfolio.
- Expenses: Operating expenses increased to $5.37 million from $4.91 million, largely due to higher amortization of deferred financing fees ($0.73 million vs. $0.18 million) associated with credit facility amendments.
- Portfolio Valuation: The portfolio fair value declined to $385.10 million from $407.93 million at September 30, 2008, representing a fair value of approximately 87% of cost.
Guidance, Outlook, Risks, and Unusual Items
- Credit Facility Maturity: The Company's $300 million revolving credit facility (DB Facility) matures on May 21, 2009. Management noted significant uncertainty regarding renewal or refinancing due to deteriorating credit markets. Effective April 14, 2009, the facility was reduced to $162 million to facilitate refinancing efforts.
- Asset Sales: Subsequent to March 31, 2009, the Company sold 13 syndicated loans for net proceeds of $22.5 million (cost basis $30.4 million) to pay down debt and manage liquidity.
- Valuation Methodology: Due to market illiquidity, the Company utilized internally-developed Discounted Cash Flow (DCF) methodologies to value approximately $33.7 million (8.8%) of its syndicated loan portfolio, as indicative bid prices were deemed unreliable.
- Non-Accrual Status: Three investments (Badanco, CCS, and U.S. Healthcare) were on non-accrual status as of March 31, 2009, with an aggregate cost basis of approximately $10.7 million.
- Equity Issuance Constraints: The Company's stock traded at a significant discount to Net Asset Value ($6.26 market price vs. $12.10 NAV). While stockholders approved the sale of shares below NAV in February 2009, regulatory constraints and market conditions limit capital raising capabilities.
- Distributions: The Company declared monthly distributions of $0.14 per share for January, February, and March 2009. The April 2009 distribution was reduced to $0.07 per share pending the outcome of credit facility refinancing.
Investor Verification Checklist
- Credit Facility Renewal: Verify the status of the DB Facility renewal or replacement, given the May 21, 2009 maturity date and the reduction in capacity to $162 million.
- Realized Losses on Sales: Confirm the final realized losses on the 13 syndicated loans sold subsequent to the quarter-end (sold for $22.5M vs. $30.4M cost).
- Non-Accrual Portfolio: Monitor the status of the three non-accrual loans (Badanco, CCS, U.S. Healthcare) and potential write-downs.
- Valuation Sensitivity: Assess the impact of the DCF valuation methodology on the $33.7 million portion of the portfolio and the potential for further unrealized depreciation if market conditions worsen.
- Distribution Sustainability: Evaluate the ability to maintain quarterly distributions if refinancing costs increase or if the Company is forced to sell assets at a loss to service debt.